
Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review
Pfizer Inc. announced today that it will discontinue the development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist under investigation for chronic weight management. The decision follows a comprehensive review of clinical trial data, …